China’s National Healthcare Security Administration (NHSA) has released its first comprehensive update on the implementation of the Commercial Insurance Innovative Drug Catalog, signaling a critical shift toward a multi-tiered medical security system. Launched at the start of 2026, the initiative aims to provide coverage for high-value, innovative therapies that fall outside the scope of the country’s Basic Medical Insurance (BMI). Huang Xinyu, director of the NHSA’s Medical Service Management Department, reported that the policy’s rollout has met expectations, with drugs from the commercial list now available in nearly 1,500 designated medical institutions—a twofold increase since the beginning of the year.
The commercial catalog currently features 19 drugs selected for their high clinical value and significant patient benefits, though their costs remain too high for the state-run BMI to absorb. By segregating these treatments into a separate commercial tier, Beijing is attempting to balance the fiscal sustainability of the state fund with the need to support pharmaceutical innovation. The NHSA noted that over 100 'Hui Min Bao' products—the popular, city-level affordable commercial insurance schemes—have already integrated these innovative drugs into their coverage frameworks, providing a vital bridge for patients requiring advanced care.
Despite the progress, the NHSA acknowledged that the commercial catalog remains a 'recommendation' rather than a mandate, leading to some friction in implementation across different regions and insurance providers. The industry still faces structural bottlenecks in how commercial health insurance (CHI) interacts with hospital procurement systems. However, the momentum for 2026 appears strong, with the NHSA receiving over 800 adjustment applications for the upcoming catalog revision cycle. This surge in interest from pharmaceutical companies suggests a growing recognition that the commercial insurance market will become a primary driver for high-end drug sales in China.
For the state-run BMI, the focus remains on 'protecting the basics.' While the state fund continues to expand—covering over 3,000 western and traditional Chinese medicines—the NHSA is increasingly looking to the commercial sector to shoulder the burden of breakthrough treatments. This division of labor is essential as China grapples with an aging population and the soaring costs of modern oncology and rare disease therapies. The upcoming 2026 catalog adjustment, scheduled for release in November, is expected to further refine this boundary between state responsibility and commercial opportunity.